1 Market Overview
1.1 Inactivated Poliovirus Vaccine Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Inactivated Poliovirus Vaccine Revenue by Type: 2020 Versus 2024 Versus 2031
1.2.2 Human Diploid Cell
1.2.3 Monkey Kidney Cell
1.3 Market Analysis by Application
1.3.1 Overview: Global Inactivated Poliovirus Vaccine Revenue by Application: 2020 Versus 2024 Versus 2031
1.3.2 Public
1.3.3 Private
1.4 Global Inactivated Poliovirus Vaccine Market Size & Forecast
1.4.1 Global Inactivated Poliovirus Vaccine Sales in Value (2020 & 2024 & 2031)
1.4.2 Global Inactivated Poliovirus Vaccine Sales in Volume (2020-2031)
1.4.3 Global Inactivated Poliovirus Vaccine Price (2020-2031)
1.5 Global Inactivated Poliovirus Vaccine Production Capacity Analysis
1.5.1 Global Inactivated Poliovirus Vaccine Total Production Capacity (2020-2031)
1.5.2 Global Inactivated Poliovirus Vaccine Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Inactivated Poliovirus Vaccine Market Drivers
1.6.2 Inactivated Poliovirus Vaccine Market Restraints
1.6.3 Inactivated Poliovirus Vaccine Trends Analysis
2 Manufacturers Profiles
2.1 Sanofi
2.1.1 Sanofi Details
2.1.2 Sanofi Major Business
2.1.3 Sanofi Inactivated Poliovirus Vaccine Product and Services
2.1.4 Sanofi Inactivated Poliovirus Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2021, 2022, 2023, and 2024)
2.2 GSK
2.2.1 GSK Details
2.2.2 GSK Major Business
2.2.3 GSK Inactivated Poliovirus Vaccine Product and Services
2.2.4 GSK Inactivated Poliovirus Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2021, 2022, 2023, and 2024)
2.3 Serum Institute (Bilthoven Biologicals)
2.3.1 Serum Institute (Bilthoven Biologicals) Details
2.3.2 Serum Institute (Bilthoven Biologicals) Major Business
2.3.3 Serum Institute (Bilthoven Biologicals) Inactivated Poliovirus Vaccine Product and Services
2.3.4 Serum Institute (Bilthoven Biologicals) Inactivated Poliovirus Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2021, 2022, 2023, and 2024)
2.4 IMBCA
2.4.1 IMBCA Details
2.4.2 IMBCA Major Business
2.4.3 IMBCA Inactivated Poliovirus Vaccine Product and Services
2.4.4 IMBCA Inactivated Poliovirus Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2021, 2022, 2023, and 2024)
3 Inactivated Poliovirus Vaccine Breakdown Data by Manufacturer
3.1 Global Inactivated Poliovirus Vaccine Sales in Volume by Manufacturer (2021, 2022, 2023, and 2024)
3.2 Global Inactivated Poliovirus Vaccine Revenue by Manufacturer (2021, 2022, 2023, and 2024)
3.3 Key Manufacturer Market Position in Inactivated Poliovirus Vaccine
3.4 Market Concentration Rate
3.4.1 Top 3 Inactivated Poliovirus Vaccine Manufacturer Market Share in 2024
3.4.2 Top 6 Inactivated Poliovirus Vaccine Manufacturer Market Share in 2024
3.5 Global Inactivated Poliovirus Vaccine Production Capacity by Company: 2023 VS 2024
3.6 Manufacturer by Geography: Head Office and Inactivated Poliovirus Vaccine Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global Inactivated Poliovirus Vaccine Market Size by Region
4.1.1 Global Inactivated Poliovirus Vaccine Sales in Volume by Region (2020-2031)
4.1.2 Global Inactivated Poliovirus Vaccine Revenue by Region (2020-2031)
4.2 North America Inactivated Poliovirus Vaccine Revenue (2020-2031)
4.3 Europe Inactivated Poliovirus Vaccine Revenue (2020-2031)
4.4 Asia-Pacific Inactivated Poliovirus Vaccine Revenue (2020-2031)
4.5 South America Inactivated Poliovirus Vaccine Revenue (2020-2031)
4.6 Middle East and Africa Inactivated Poliovirus Vaccine Revenue (2020-2031)
5 Market Segment by Type
5.1 Global Inactivated Poliovirus Vaccine Sales in Volume by Type (2020-2031)
5.2 Global Inactivated Poliovirus Vaccine Revenue by Type (2020-2031)
5.3 Global Inactivated Poliovirus Vaccine Price by Type (2020-2031)
6 Market Segment by Application
6.1 Global Inactivated Poliovirus Vaccine Sales in Volume by Application (2020-2031)
6.2 Global Inactivated Poliovirus Vaccine Revenue by Application (2020-2031)
6.3 Global Inactivated Poliovirus Vaccine Price by Application (2020-2031)
7 North America by Country, by Type, and by Application
7.1 North America Inactivated Poliovirus Vaccine Sales by Type (2020-2031)
7.2 North America Inactivated Poliovirus Vaccine Sales by Application (2020-2031)
7.3 North America Inactivated Poliovirus Vaccine Market Size by Country
7.3.1 North America Inactivated Poliovirus Vaccine Sales in Volume by Country (2020-2031)
7.3.2 North America Inactivated Poliovirus Vaccine Revenue by Country (2020-2031)
7.3.3 United States Market Size and Forecast (2020-2031)
7.3.4 Canada Market Size and Forecast (2020-2031)
7.3.5 Mexico Market Size and Forecast (2020-2031)
8 Europe by Country, by Type, and by Application
8.1 Europe Inactivated Poliovirus Vaccine Sales by Type (2020-2031)
8.2 Europe Inactivated Poliovirus Vaccine Sales by Application (2020-2031)
8.3 Europe Inactivated Poliovirus Vaccine Market Size by Country
8.3.1 Europe Inactivated Poliovirus Vaccine Sales in Volume by Country (2020-2031)
8.3.2 Europe Inactivated Poliovirus Vaccine Revenue by Country (2020-2031)
8.3.3 Germany Market Size and Forecast (2020-2031)
8.3.4 France Market Size and Forecast (2020-2031)
8.3.5 United Kingdom Market Size and Forecast (2020-2031)
8.3.6 Russia Market Size and Forecast (2020-2031)
8.3.7 Italy Market Size and Forecast (2020-2031)
9 Asia-Pacific by Region, by Type, and by Application
9.1 Asia-Pacific Inactivated Poliovirus Vaccine Sales by Type (2020-2031)
9.2 Asia-Pacific Inactivated Poliovirus Vaccine Sales by Application (2020-2031)
9.3 Asia-Pacific Inactivated Poliovirus Vaccine Market Size by Region
9.3.1 Asia-Pacific Inactivated Poliovirus Vaccine Sales in Volume by Region (2020-2031)
9.3.2 Asia-Pacific Inactivated Poliovirus Vaccine Revenue by Region (2020-2031)
9.3.3 China Market Size and Forecast (2020-2031)
9.3.4 Japan Market Size and Forecast (2020-2031)
9.3.5 Korea Market Size and Forecast (2020-2031)
9.3.6 India Market Size and Forecast (2020-2031)
9.3.7 Southeast Asia Market Size and Forecast (2020-2031)
9.3.8 Australia Market Size and Forecast (2020-2031)
10 South America by Region, by Type, and by Application
10.1 South America Inactivated Poliovirus Vaccine Sales by Type (2020-2031)
10.2 South America Inactivated Poliovirus Vaccine Sales by Application (2020-2031)
10.3 South America Inactivated Poliovirus Vaccine Market Size by Country
10.3.1 South America Inactivated Poliovirus Vaccine Sales in Volume by Country (2020-2031)
10.3.2 South America Inactivated Poliovirus Vaccine Revenue by Country (2020-2031)
10.3.3 Brazil Market Size and Forecast (2020-2031)
10.3.4 Argentina Market Size and Forecast (2020-2031)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa Inactivated Poliovirus Vaccine Sales by Type (2020-2031)
11.2 Middle East & Africa Inactivated Poliovirus Vaccine Sales by Application (2020-2031)
11.3 Middle East & Africa Inactivated Poliovirus Vaccine Market Size by Country
11.3.1 Middle East & Africa Inactivated Poliovirus Vaccine Sales in Volume by Country (2020-2031)
11.3.2 Middle East & Africa Inactivated Poliovirus Vaccine Revenue by Country (2020-2031)
11.3.3 Turkey Market Size and Forecast (2020-2031)
11.3.4 Egypt Market Size and Forecast (2020-2031)
11.3.5 Saudi Arabia Market Size and Forecast (2020-2031)
11.3.6 South Africa Market Size and Forecast (2020-2031)
12 Raw Material and Industry Chain
12.1 Raw Material of Inactivated Poliovirus Vaccine and Key Manufacturers
12.2 Manufacturing Costs Percentage of Inactivated Poliovirus Vaccine
12.3 Inactivated Poliovirus Vaccine Production Process
12.4 Inactivated Poliovirus Vaccine Industrial Chain
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 Inactivated Poliovirus Vaccine Typical Distributors
13.3 Inactivated Poliovirus Vaccine Typical Customers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Research Process and Data Source
15.3 Disclaimer

List of Tables
Table 1. Global Inactivated Poliovirus Vaccine Revenue by Type, (USD Million), 2020 & 2024 & 2031
Table 2. Global Inactivated Poliovirus Vaccine Revenue by Application, (USD Million), 2020 & 2024 & 2031
Table 3. Sanofi Basic Information, Manufacturing Base and Competitors
Table 4. Sanofi Major Business
Table 5. Sanofi Inactivated Poliovirus Vaccine Product and Services
Table 6. Sanofi Inactivated Poliovirus Vaccine Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2021, 2022, 2023, and 2024)
Table 7. GSK Basic Information, Manufacturing Base and Competitors
Table 8. GSK Major Business
Table 9. GSK Inactivated Poliovirus Vaccine Product and Services
Table 10. GSK Inactivated Poliovirus Vaccine Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2021, 2022, 2023, and 2024)
Table 11. Serum Institute (Bilthoven Biologicals) Basic Information, Manufacturing Base and Competitors
Table 12. Serum Institute (Bilthoven Biologicals) Major Business
Table 13. Serum Institute (Bilthoven Biologicals) Inactivated Poliovirus Vaccine Product and Services
Table 14. Serum Institute (Bilthoven Biologicals) Inactivated Poliovirus Vaccine Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2021, 2022, 2023, and 2024)
Table 15. IMBCA Basic Information, Manufacturing Base and Competitors
Table 16. IMBCA Major Business
Table 17. IMBCA Inactivated Poliovirus Vaccine Product and Services
Table 18. IMBCA Inactivated Poliovirus Vaccine Sales (K Units), Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2021, 2022, 2023, and 2024)
Table 19. Global Inactivated Poliovirus Vaccine Sales by Manufacturer (2021, 2022, 2023, and 2024) & (K Units)
Table 20. Global Inactivated Poliovirus Vaccine Revenue by Manufacturer (2021, 2022, 2023, and 2024) & (USD Million)
Table 21. Market Position of Manufacturers in Inactivated Poliovirus Vaccine, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2024
Table 22. Global Inactivated Poliovirus Vaccine Production Capacity by Company, (K Units): 2023 VS 2024
Table 23. Head Office and Inactivated Poliovirus Vaccine Production Site of Key Manufacturer
Table 24. Inactivated Poliovirus Vaccine New Entrant and Capacity Expansion Plans
Table 25. Inactivated Poliovirus Vaccine Mergers & Acquisitions in the Past Five Years
Table 26. Global Inactivated Poliovirus Vaccine Sales by Region (2020-2024) & (K Units)
Table 27. Global Inactivated Poliovirus Vaccine Sales by Region (2025-2031) & (K Units)
Table 28. Global Inactivated Poliovirus Vaccine Revenue by Region (2020-2024) & (USD Million)
Table 29. Global Inactivated Poliovirus Vaccine Revenue by Region (2025-2031) & (USD Million)
Table 30. Global Inactivated Poliovirus Vaccine Sales by Type (2020-2024) & (K Units)
Table 31. Global Inactivated Poliovirus Vaccine Sales by Type (2025-2031) & (K Units)
Table 32. Global Inactivated Poliovirus Vaccine Revenue by Type (2020-2024) & (USD Million)
Table 33. Global Inactivated Poliovirus Vaccine Revenue by Type (2025-2031) & (USD Million)
Table 34. Global Inactivated Poliovirus Vaccine Price by Type (2020-2024) & (USD/Unit)
Table 35. Global Inactivated Poliovirus Vaccine Price by Type (2025-2031) & (USD/Unit)
Table 36. Global Inactivated Poliovirus Vaccine Sales by Application (2020-2024) & (K Units)
Table 37. Global Inactivated Poliovirus Vaccine Sales by Application (2025-2031) & (K Units)
Table 38. Global Inactivated Poliovirus Vaccine Revenue by Application (2020-2024) & (USD Million)
Table 39. Global Inactivated Poliovirus Vaccine Revenue by Application (2025-2031) & (USD Million)
Table 40. Global Inactivated Poliovirus Vaccine Price by Application (2020-2024) & (USD/Unit)
Table 41. Global Inactivated Poliovirus Vaccine Price by Application (2025-2031) & (USD/Unit)
Table 42. North America Inactivated Poliovirus Vaccine Sales by Country (2020-2024) & (K Units)
Table 43. North America Inactivated Poliovirus Vaccine Sales by Country (2025-2031) & (K Units)
Table 44. North America Inactivated Poliovirus Vaccine Revenue by Country (2020-2024) & (USD Million)
Table 45. North America Inactivated Poliovirus Vaccine Revenue by Country (2025-2031) & (USD Million)
Table 46. North America Inactivated Poliovirus Vaccine Sales by Type (2020-2024) & (K Units)
Table 47. North America Inactivated Poliovirus Vaccine Sales by Type (2025-2031) & (K Units)
Table 48. North America Inactivated Poliovirus Vaccine Sales by Application (2020-2024) & (K Units)
Table 49. North America Inactivated Poliovirus Vaccine Sales by Application (2025-2031) & (K Units)
Table 50. Europe Inactivated Poliovirus Vaccine Sales by Country (2020-2024) & (K Units)
Table 51. Europe Inactivated Poliovirus Vaccine Sales by Country (2025-2031) & (K Units)
Table 52. Europe Inactivated Poliovirus Vaccine Revenue by Country (2020-2024) & (USD Million)
Table 53. Europe Inactivated Poliovirus Vaccine Revenue by Country (2025-2031) & (USD Million)
Table 54. Europe Inactivated Poliovirus Vaccine Sales by Type (2020-2024) & (K Units)
Table 55. Europe Inactivated Poliovirus Vaccine Sales by Type (2025-2031) & (K Units)
Table 56. Europe Inactivated Poliovirus Vaccine Sales by Application (2020-2024) & (K Units)
Table 57. Europe Inactivated Poliovirus Vaccine Sales by Application (2025-2031) & (K Units)
Table 58. Asia-Pacific Inactivated Poliovirus Vaccine Sales by Region (2020-2024) & (K Units)
Table 59. Asia-Pacific Inactivated Poliovirus Vaccine Sales by Region (2025-2031) & (K Units)
Table 60. Asia-Pacific Inactivated Poliovirus Vaccine Revenue by Region (2020-2024) & (USD Million)
Table 61. Asia-Pacific Inactivated Poliovirus Vaccine Revenue by Region (2025-2031) & (USD Million)
Table 62. Asia-Pacific Inactivated Poliovirus Vaccine Sales by Type (2020-2024) & (K Units)
Table 63. Asia-Pacific Inactivated Poliovirus Vaccine Sales by Type (2025-2031) & (K Units)
Table 64. Asia-Pacific Inactivated Poliovirus Vaccine Sales by Application (2020-2024) & (K Units)
Table 65. Asia-Pacific Inactivated Poliovirus Vaccine Sales by Application (2025-2031) & (K Units)
Table 66. South America Inactivated Poliovirus Vaccine Sales by Country (2020-2024) & (K Units)
Table 67. South America Inactivated Poliovirus Vaccine Sales by Country (2025-2031) & (K Units)
Table 68. South America Inactivated Poliovirus Vaccine Revenue by Country (2020-2024) & (USD Million)
Table 69. South America Inactivated Poliovirus Vaccine Revenue by Country (2025-2031) & (USD Million)
Table 70. South America Inactivated Poliovirus Vaccine Sales by Type (2020-2024) & (K Units)
Table 71. South America Inactivated Poliovirus Vaccine Sales by Type (2025-2031) & (K Units)
Table 72. South America Inactivated Poliovirus Vaccine Sales by Application (2020-2024) & (K Units)
Table 73. South America Inactivated Poliovirus Vaccine Sales by Application (2025-2031) & (K Units)
Table 74. Middle East & Africa Inactivated Poliovirus Vaccine Sales by Region (2020-2024) & (K Units)
Table 75. Middle East & Africa Inactivated Poliovirus Vaccine Sales by Region (2025-2031) & (K Units)
Table 76. Middle East & Africa Inactivated Poliovirus Vaccine Revenue by Region (2020-2024) & (USD Million)
Table 77. Middle East & Africa Inactivated Poliovirus Vaccine Revenue by Region (2025-2031) & (USD Million)
Table 78. Middle East & Africa Inactivated Poliovirus Vaccine Sales by Type (2020-2024) & (K Units)
Table 79. Middle East & Africa Inactivated Poliovirus Vaccine Sales by Type (2025-2031) & (K Units)
Table 80. Middle East & Africa Inactivated Poliovirus Vaccine Sales by Application (2020-2024) & (K Units)
Table 81. Middle East & Africa Inactivated Poliovirus Vaccine Sales by Application (2025-2031) & (K Units)
Table 82. Inactivated Poliovirus Vaccine Raw Material
Table 83. Key Manufacturers of Inactivated Poliovirus Vaccine Raw Materials
Table 84. Direct Channel Pros & Cons
Table 85. Indirect Channel Pros & Cons
Table 86. Inactivated Poliovirus Vaccine Typical Distributors
Table 87. Inactivated Poliovirus Vaccine Typical Customers
List of Figures
Figure 1. Inactivated Poliovirus Vaccine Picture
Figure 2. Global Inactivated Poliovirus Vaccine Revenue Market Share by Type in 2024
Figure 3. Human Diploid Cell
Figure 4. Monkey Kidney Cell
Figure 5. Global Inactivated Poliovirus Vaccine Revenue Market Share by Application in 2024
Figure 6. Public
Figure 7. Private
Figure 8. Global Inactivated Poliovirus Vaccine Revenue, (USD Million) & (K Units): 2020 & 2024 & 2031
Figure 9. Global Inactivated Poliovirus Vaccine Revenue and Forecast (2020-2031) & (USD Million)
Figure 10. Global Inactivated Poliovirus Vaccine Sales (2020-2031) & (K Units)
Figure 11. Global Inactivated Poliovirus Vaccine Price (2020-2031) & (USD/Unit)
Figure 12. Global Inactivated Poliovirus Vaccine Production Capacity (2020-2031) & (K Units)
Figure 13. Global Inactivated Poliovirus Vaccine Production Capacity by Geographic Region: 2024 VS 2031
Figure 14. Inactivated Poliovirus Vaccine Market Drivers
Figure 15. Inactivated Poliovirus Vaccine Market Restraints
Figure 16. Inactivated Poliovirus Vaccine Market Trends
Figure 17. Global Inactivated Poliovirus Vaccine Sales Market Share by Manufacturer in 2024
Figure 18. Global Inactivated Poliovirus Vaccine Revenue Market Share by Manufacturer in 2024
Figure 19. Inactivated Poliovirus Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2024
Figure 20. Top 3 Inactivated Poliovirus Vaccine Manufacturer (Revenue) Market Share in 2024
Figure 21. Top 6 Inactivated Poliovirus Vaccine Manufacturer (Revenue) Market Share in 2024
Figure 22. Global Inactivated Poliovirus Vaccine Sales Market Share by Region (2020-2031)
Figure 23. Global Inactivated Poliovirus Vaccine Revenue Market Share by Region (2020-2031)
Figure 24. North America Inactivated Poliovirus Vaccine Revenue (2020-2031) & (USD Million)
Figure 25. Europe Inactivated Poliovirus Vaccine Revenue (2020-2031) & (USD Million)
Figure 26. Asia-Pacific Inactivated Poliovirus Vaccine Revenue (2020-2031) & (USD Million)
Figure 27. South America Inactivated Poliovirus Vaccine Revenue (2020-2031) & (USD Million)
Figure 28. Middle East & Africa Inactivated Poliovirus Vaccine Revenue (2020-2031) & (USD Million)
Figure 29. Global Inactivated Poliovirus Vaccine Sales Market Share by Type (2020-2031)
Figure 30. Global Inactivated Poliovirus Vaccine Revenue Market Share by Type (2020-2031)
Figure 31. Global Inactivated Poliovirus Vaccine Price by Type (2020-2031) & (USD/Unit)
Figure 32. Global Inactivated Poliovirus Vaccine Sales Market Share by Application (2020-2031)
Figure 33. Global Inactivated Poliovirus Vaccine Revenue Market Share by Application (2020-2031)
Figure 34. Global Inactivated Poliovirus Vaccine Price by Application (2020-2031) & (USD/Unit)
Figure 35. North America Inactivated Poliovirus Vaccine Sales Market Share by Type (2020-2031)
Figure 36. North America Inactivated Poliovirus Vaccine Sales Market Share by Application (2020-2031)
Figure 37. North America Inactivated Poliovirus Vaccine Sales Market Share by Country (2020-2031)
Figure 38. North America Inactivated Poliovirus Vaccine Revenue Market Share by Country (2020-2031)
Figure 39. United States Inactivated Poliovirus Vaccine Revenue and Growth Rate (2020-2031) & (USD Million)
Figure 40. Canada Inactivated Poliovirus Vaccine Revenue and Growth Rate (2020-2031) & (USD Million)
Figure 41. Mexico Inactivated Poliovirus Vaccine Revenue and Growth Rate (2020-2031) & (USD Million)
Figure 42. Europe Inactivated Poliovirus Vaccine Sales Market Share by Type (2020-2031)
Figure 43. Europe Inactivated Poliovirus Vaccine Sales Market Share by Application (2020-2031)
Figure 44. Europe Inactivated Poliovirus Vaccine Sales Market Share by Country (2020-2031)
Figure 45. Europe Inactivated Poliovirus Vaccine Revenue Market Share by Country (2020-2031)
Figure 46. Germany Inactivated Poliovirus Vaccine Revenue and Growth Rate (2020-2031) & (USD Million)
Figure 47. France Inactivated Poliovirus Vaccine Revenue and Growth Rate (2020-2031) & (USD Million)
Figure 48. United Kingdom Inactivated Poliovirus Vaccine Revenue and Growth Rate (2020-2031) & (USD Million)
Figure 49. Russia Inactivated Poliovirus Vaccine Revenue and Growth Rate (2020-2031) & (USD Million)
Figure 50. Italy Inactivated Poliovirus Vaccine Revenue and Growth Rate (2020-2031) & (USD Million)
Figure 51. Asia-Pacific Inactivated Poliovirus Vaccine Sales Market Share by Region (2020-2031)
Figure 52. Asia-Pacific Inactivated Poliovirus Vaccine Sales Market Share by Application (2020-2031)
Figure 53. Asia-Pacific Inactivated Poliovirus Vaccine Sales Market Share by Region (2020-2031)
Figure 54. Asia-Pacific Inactivated Poliovirus Vaccine Revenue Market Share by Region (2020-2031)
Figure 55. China Inactivated Poliovirus Vaccine Revenue and Growth Rate (2020-2031) & (USD Million)
Figure 56. Japan Inactivated Poliovirus Vaccine Revenue and Growth Rate (2020-2031) & (USD Million)
Figure 57. Korea Inactivated Poliovirus Vaccine Revenue and Growth Rate (2020-2031) & (USD Million)
Figure 58. India Inactivated Poliovirus Vaccine Revenue and Growth Rate (2020-2031) & (USD Million)
Figure 59. Southeast Asia Inactivated Poliovirus Vaccine Revenue and Growth Rate (2020-2031) & (USD Million)
Figure 60. Australia Inactivated Poliovirus Vaccine Revenue and Growth Rate (2020-2031) & (USD Million)
Figure 61. South America Inactivated Poliovirus Vaccine Sales Market Share by Type (2020-2031)
Figure 62. South America Inactivated Poliovirus Vaccine Sales Market Share by Application (2020-2031)
Figure 63. South America Inactivated Poliovirus Vaccine Sales Market Share by Country (2020-2031)
Figure 64. South America Inactivated Poliovirus Vaccine Revenue Market Share by Country (2020-2031)
Figure 65. Brazil Inactivated Poliovirus Vaccine Revenue and Growth Rate (2020-2031) & (USD Million)
Figure 66. Argentina Inactivated Poliovirus Vaccine Revenue and Growth Rate (2020-2031) & (USD Million)
Figure 67. Middle East & Africa Inactivated Poliovirus Vaccine Sales Market Share by Type (2020-2031)
Figure 68. Middle East & Africa Inactivated Poliovirus Vaccine Sales Market Share by Application (2020-2031)
Figure 69. Middle East & Africa Inactivated Poliovirus Vaccine Sales Market Share by Region (2020-2031)
Figure 70. Middle East & Africa Inactivated Poliovirus Vaccine Revenue Market Share by Region (2020-2031)
Figure 71. Turkey Inactivated Poliovirus Vaccine Revenue and Growth Rate (2020-2031) & (USD Million)
Figure 72. Egypt Inactivated Poliovirus Vaccine Revenue and Growth Rate (2020-2031) & (USD Million)
Figure 73. Saudi Arabia Inactivated Poliovirus Vaccine Revenue and Growth Rate (2020-2031) & (USD Million)
Figure 74. South Africa Inactivated Poliovirus Vaccine Revenue and Growth Rate (2020-2031) & (USD Million)
Figure 75. Manufacturing Cost Structure Analysis of Inactivated Poliovirus Vaccine in 2024
Figure 76. Manufacturing Process Analysis of Inactivated Poliovirus Vaccine
Figure 77. Inactivated Poliovirus Vaccine Industrial Chain
Figure 78. Sales Channel: Direct Channel vs Indirect Channel
Figure 79. Methodology
Figure 80. Research Process and Data Source

※参考情報 不活化ポリオワクチン（Inactivated Poliovirus Vaccine、IPV）は、ポリオウイルスによる感染症である急性弛緩性脊髄炎を予防するために使用されるワクチンです。このワクチンは、ウイルスを不活化または死滅させて作られており、接種を受けた人の体内に免疫応答を引き起こし、実際に感染することなくポリオウイルスに対して防御力を高める役割を果たします。 不活化ポリオワクチンは、1955年にジョナス・ソークによって初めて開発されました。これにより、ポリオウイルスに対する予防策が大きく前進しました。ポリオウイルスには、1型、2型、3型の3つの血清型が存在しますが、不活化ポリオワクチンはこれらの全ての型に対して免疫を形成することができるように設計されています。 このワクチンの大きな特徴の一つは、安全性が高いことです。不活化ポリオワクチンは、ウイルスが完全に不活化されているため、接種された人がポリオに感染するリスクはありません。さらに、アナフィラキシーや重篤な副作用の発生率も極めて低く、副作用としては、局所的な痛みや腫れ、発熱などが報告されることがありますが、これらは通常軽度で一時的です。 IPVは主に注射によって投与されます。通常、初回接種は生後2ヶ月から開始し、その後数回の追加接種が推奨されます。具体的には、初めの接種は2ヶ月頃、次は4ヶ月頃、さらに6〜18ヶ月頃に行われることが一般的です。最終的に、4〜6歳の頃に追加の接種が行われる場合があります。このスケジュールに従うことで、全てのポリオウイルス型に対して適切な免疫が形成されることが期待されます。 不活化ポリオワクチンは、いくつかの異なる製品が市販されています。その中には、単独で使用される製剤もあれば、他のワクチンと組み合わせて使用される混合ワクチンもあります。組み合わせワクチンは、例えば、DTPaワクチン（ジフテリア、百日咳、破傷風の混合ワクチン）やMMRワクチン（麻疹、おたふく風邪、風疹の混合ワクチン）といった他のワクチンと一緒に接種されることが多いです。 不活化ポリオワクチンの主な用途は、ポリオの予防です。ポリオは世界中で特に子供に深刻な影響を与える病気であり、感染すると神経系に影響を与え、最終的には麻痺を引き起こす可能性があります。この病気は、一度麻痺が発生すると回復が難しいため、予防が極めて重要です。世界保健機関（WHO）および各国の保健機関は、ポリオ根絶のために不活化ポリオワクチンの接種を推奨しています。 関連技術としては、ワクチン開発において重要な役割を果たす技術がいくつかあります。まず、培養技術があります。不活化ポリオワクチンを製造するためには、まずウイルスを細胞培養系で増殖させます。一般的には恒常的な細胞株を使い、その中でウイルスを増やします。次に、得られたウイルスを化学的手法や物理的手法によって不活化し、ワクチン成分を精製します。 また、アジュバント技術も重要です。アジュバントとは、ワクチンの効果を高めるために添加される物質です。不活化ポリオワクチンでは、通常、アジュバントを加えることで免疫応答を増強し、より長期的な免疫を形成することが可能になります。 さらに、モニタリング技術も関連しています。ワクチン接種後の免疫の状態を確認するために、エライサーや中和抗体試験といった検査が行われます。これにより、ワクチンが適切に機能しているかどうかを評価し、さらなる接種の必要性を判断できます。 不活化ポリオワクチンの重要性は、近年のポリオ根絶運動においても如実に示されています。特に、世界中でポリオウイルス感染の報告が減少している中、ワクチンプログラムの進展により、多くの国でポリオが根絶されつつあります。従って、このワクチンは公共の健康を維持するために欠かせない存在であると言えるでしょう。 また、IPVは国際的な旅行や移住に伴うリスク管理としても重要です。一部の国や地域ではポリオが依然として流行しているため、旅行者は接種を受けておくことが推奨されます。これにより、感染の拡大を防ぎ、自国への持ち帰りを防ぐことができるため、個人及び公共の健康を保護する重要な手段となります。 総じて、不活化ポリオワクチンはその安全性と免疫生成の効果から、ポリオウイルスによる感染症の予防において極めて重要な役割を果たしています。今後も、この技術を基にしたさらなる研究開発が進められることで、ワクチンの進化や効果の向上が期待されます。これにより、ポリオの根絶という目標に向けた努力が続けられることになるでしょう。

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/